Sir,
A 55-year-old man presented with histopathologically proven clear cell type of renal cell carcinoma (RCC). He underwent the right radical nephrectomy and received radiotherapy to bilateral pelvic bones, right femur, D7-D9 vertebrae, and right scapulae. He was on sunitinib therapy and came to our department for 18 F-fludeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) scan for restaging. In the maximum intensity projection image [ Figure 1a ], it showed recurrence in the right renal bed and metastases to bilateral lungs and multiple skeletal sites including a rare site of hyoid bone metastases (black arrow). Transaxial PET/CT and CT images [ Figure 1b and c] showed lytic lesion in hyoid bone with increased tracer uptake (white arrow), suggestive of hyoid bone metastasis.
FDG-PET/CT is useful for the restaging of patients with RCC.
PET has a diagnostic accuracy of 89% for the restaging of RCC. [1] It has a diagnostic accuracy of 84% for classifying biopsy proven anatomic lesions as malignant or benign. [1] However, it has a high false-positive rate for the initial detection of primary RCC due to the presence of physiological excretion of FDG in the kidneys. [2] Postnephrectomy, many patients show recurrence. The most common sites for recurrence of RCC include lung, regional lymph nodes, bone, liver, and brain. [3] For the detection of skeletal metastases, FDG-PET/CT and bone scans have been compared. The sensitivity and specificity of FDG-PET/CT were 100% whereas the sensitivity of bone scan was 77.5% and specificity was 59.6%. [4] 
